Glycosaminoglycans degradation

Glycosaminoglycans degradation is a biological catabolic process, not a molecular target, carried out primarily by lysosomal enzymes such as glycosidases and sulfatases[2][5]. Glycosaminoglycans (GAGs) are long linear polysaccharides present in the extracellular matrix and on cell surfaces. Their degradation involves stepwise cleavage by endo- and exo-type hydrolases within lysosomes[1]. Defective degradation leads to lysosomal storage disorders, notably mucopolysaccharidoses[1]. Although drugs and enzymes (such as chondroitinase ABC) are used to modulate GAG degradation for research and therapeutic purposes, \"Glycosaminoglycans degradation\" by itself is not a receptor, enzyme, or molecular entity, but the collective action of various enzymes and processes[2][4][5]. Thus, while relevant in disease and therapeutic contexts, it does not conform to valid molecular target naming conventions, and listing it as a target is incorrect under standard biomedical taxonomies.

Other names

Glycosaminoglycan catabolismGAGs degradation

Enzymatic cleavage of glycosaminoglycan chains leading to monomer release (by exo- and endo-type hydrolases)